

Louisiana Department of Health Bureau of Health Services Financing

MEMORANDUM

DATE: December 22, 2021

TO: All Louisiana Medicaid Prescribing Providers and Pharmacists

FROM: Patrick Gillies, Medicaid Executive Director

SUBJECT: Louisiana Medicaid Pharmacy Point of Sale Quantity Limits-

January 2022

Effective January 1, 2022, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review (DUR) Board, will implement quantity limits for select medications. The quantity limits apply to pharmacy claims submitted to FFS and MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections, and UnitedHealthcare).

Quantity Limit

The agents listed in the chart below have quantity limits at Point of Sale (POS).

Medication (Generic – Brand Example)	Quantity Limit	
Alirocumab (Praluent®)	2 injections (2ml) per 28 days	
Evolocumab (Repatha®) 140mg/ml	2 injections (2ml) per 28 days	
Evolocumab (Repatha®) 420mg/3.5ml	2 injections (7ml) per 28 days	
Lemborexant (Dayvigo®)	7 tablets per rolling 30 days (for recipients who are naïve to sedative/hypnotics)*; 15 tablets per rolling 30 days (for recipients who are non-naïve to sedative/hypnotics)**	
Lomitapide (Juxtapid®)	60 capsules per 30 days	
Rimegepant (Nurtec® ODT)	48 units per year	
Tramadol oral solution (Qdolo®)	6 ounces (180ml) or a 7-day supply (whichever is less)***	

^{*}There is no pharmacy claim for a sedative/hypnotic agent in the previous 60-day period.

^{**}There is at least one pharmacy claim for a sedative/hypnotic agent in the previous 60-day period.

^{***}There is no pharmacy claim for an opioid in the previous 90-day period.

Point of Sale Override for Quantity Limit in the Previous Chart Excluding (Qdolo®)

Pharmacy claims for select drugs which exceed the quantity limit will deny with:

MCO Only: The pharmacy claim will deny with a NCPDP rejection code. If additional assistance is needed, contact the health plan. (See contact information at the end of this document.)

FFS Only: NCPDP rejection code 76 (Quantity and/or days' supply exceeds program maximum) mapped to

EOB code 457 (Quantity and/or days' supply exceeds program maximum)

Upon consultation with the prescriber to verify the necessity of the requested therapy, the pharmacist may override the denial by submitting the following override at POS:

NCPDP 439-E4 Field (Reason for Service Code) EX (Excessive Quantity)
NCPDP 440-E5 Field (Professional Service Code) MØ (Prescriber Consulted)
NCPDP 441-E6 Field (Result of Service Code) 1G (Filled with Prescriber Approval)

Override for Quantity Limits for Tramadol Oral Solution (Qdolo®)

Prescriptions for opioid oral liquids will have a quantity limit of 180 ml or a 7-day supply, whichever is less.

Pharmacy claims for opioid (oral) liquid formulations, which exceed the maximum quantity limit will deny with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**. If an override is requested, contact the health plan. (See contact information at the end of this document.)

FFS Only: NCPDP rejection code 76 (Quantity and/or days' supply exceeds program maximum) mapped to

EOB code 153 (Quantity Exceeds Max-MD Fax Override Form 866-797-2329)

Bypass Diagnosis Codes for Tramadol Oral Solution (Qdolo®)

Pharmacy claims for tramadol oral solution (Qdolo®) will **bypass** the quantity limit when submitted with an appropriate diagnosis code as listed in the chart below.

Diagnosis Codes that Bypass Quantity Limit for Tramadol Oral Solution (Qdolo®)

Diagnosis Description	ICD-10 Diagnosis Code(s)
Cancer	C00.*–C96.*
Palliative Care	Z51.5
Second or Third Degree Burns or Corrosions	T20.2*, T20.3*, T20.6*, T20.7*, T21.2*, T21.3*, T21.6*, T21.7*, T22.2*, T22.3*, T22.6*, T22.7*, T23.2*, T23.3*, T23.6*, T23.7*, T24.2*, T24.3*, T24.6*, T24.7*, T25.2*, T25.3*, T25.6*, T25.7*
Sickle Cell Crisis	D57.0*, D57.21*, D57.41*, D57.81*

^{*} Any number or letter or combination of up to four numbers and letters of an assigned ICD-10 diagnosis code

Additional Information:

In addition to a quantity limit, pharmacy claims for tramadol oral solution (Qdolo®) are subject to a maximum daily dose. Tramadol oral solution (Qdolo®) is limited to a maximum daily dose based on age:

- 300mg/day for recipients who are 76 years old and older; and
- 400mg/day for recipients who are 75 years old and younger.

Refer to http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf for the PDL, which is inclusive of the Louisiana Uniform Prescription Drug Prior Authorization Form, medication list, and criteria.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

Healthcare Provider	Pharmacy Help Desk	Pharmacy Help Desk Phone Number
Aetna	CVS Health	(855) 364-2977
AmeriHealth Caritas	PerformRx	(800) 684-5502
Fee for Service	Gainwell Technologies	(800) 648-0790
Healthy Blue	CVS	(833) 236-6194
Louisiana Healthcare Connections	CVS Caremark	(800) 311-0543
UnitedHealthcare	Optum Rx	(866) 328-3108

FFS and MCO Quantity Limits- January 2022 December 22, 2021 Page 4

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

PG/MB/MBW/GJS

c: Healthy Louisiana Plans Melwyn B. Wendt Gainwell Technologies